Observational studyBMC pregnancy and childbirth2025
Impact of maternal COVID-19 infection on offspring immunity and maternal-fetal outcomes at different pregnancy stages: a cohort study.
Observational study in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07257952 (An Observational Study on the Risk of Adverse Maternal and Infant Outcomes Associated With Respiratory Viral Infections Before and During Early Pregnancy), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Observational Study on the Risk of Adverse Maternal and Infant Outcomes Associated With Respiratory Viral Infections Before and During Early Pregnancy
Who cites it
2 citing papers in PubMed.
- Health-related quality of life assessed by EQ-5D among hospitalized pregnant and postpartum women with SARS-CoV-2 infection in Suzhou city.Scientific reports · 2025Article
- Presence of SARS-CoV-2 in fetal organs via intraamniotic infection.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo investigate the impact of COVID-19 infection on maternal and neonatal outcomes and immunity in pregnant women in China.
methods283 pregnant women with COVID-19 were included in the prospective observational cohort study and divided into five groups based on infection stage. Antibody levels were measured in plasma, umbilical cord blood, and breast milk, and combined with clinical data and 6-month follow-up results. We measured SARS-CoV-2 antibody levels using a chemiluminescence immunoassay and analyzed the data with the Kruskal-Wallis test, χ2 test, or Fisher's exact test.
resultsNo significant differences were found in age, BMI, weight change during pregnancy, or the incidence of gestational hypertension, gestational diabetes, gestational hypothyroidism, intrahepatic cholestasis, transaminitis, preterm birth, small for gestational age, neonatal NICU transfers, developmental delays, and hearing damage among the five groups. The incidence of COVID-19 in infants from mothers infected at different stages of pregnancy was significantly lower than in the uninfected group (P < 0.05). Maternal and umbilical cord blood showed significantly higher IgG levels in the infected group compared to the uninfected group at different stages of pregnancy (P < 0.05). The median transplacental antibody transfer ratio across all infection groups was 1.15 (0.98-1.30), with no significant differences between them. The reinfection group had significantly higher IgA levels during pregnancy compared to other groups (P < 0.05).
conclusionNo adverse outcomes were observed in mothers or infants at any stage of maternal SARS-CoV-2 infection. Antibodies in umbilical cord blood and breast milk may offer passive immunity to newborns for 1-3 months. Reinfection during pregnancy may extend this immunity without raising the risk of adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.